semaglutide erectile dysfunction The Impact of Glucagon-like Peptide-1 Receptor Agonists on Function: Friend or Foe? Is Erectile Dysfunction a Side

Before every injection at Southdowns, our pharmacist goes through a health check with you first

Clinical studies on GLP-1 receptor agonists, including Saxenda, Wegovy, Ozempic, and Mounjaro , provide valuable insight into their long-term efficacy: Saxenda (Liraglutide) A 3-year study showed: 56% of participants reached and maintained target weight loss in year one With continuous use, many maintained weight loss over 3 years Success was highest when paired with lifestyle interventions (diet + exercise) Risk of weight regain increased if Saxenda was discontinued without behavioral support Wegovy (Semaglutide) STEP 4 trial (68 weeks) showed: Patients who continued Wegovy maintained a 14.8% weight loss Those who stopped the medication regained about two-thirds of the weight within 1 year Suggests Wegovy is effective long-term , but requires ongoing treatment or strong lifestyle adherence Ozempic (Semaglutide) (used off-label for weight loss) In studies where Ozempic was used weekly: Weight loss was sustained as long as treatment continued Discontinuation led to partial weight regain , though not as rapid as in untreated individuals Works well when paired with structured eating plans Mounjaro (Tirzepatide) Strongest Long-Term Outcome to Date SURMOUNT-1 trial: After 72 weeks , participants lost up to 22.5% of body weight Even after treatment ended, those who adopted lifestyle changes were able to keep the weight off Its dual action on both GLP-1 and GIP receptors improves: Insulin sensitivity Appetite regulation Metabolism regulation Early data suggests Mounjaro has the lowest likelihood of rebound weight gain , especially when combined with follow-up care Comparing Saxenda, Wegovy, Ozempic, and Mounjaro 1

This breakdown in the clearance of oxidative stress leads directly to the core pathophysiology of conditions like ME/CFS and Long COVID: profound mitochondrial dysfunction

Tirzepatide's added GIP activity is thought to drive the larger effect on top of the shared GLP-1 pathway though weight loss is only one part of the picture, and semaglutide still has the longer cardiovascular-outcomes track record (more on that below)